Molina Healthcare Inc (MOH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-30. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.62% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Should Value Investors Buy Molina Healthcare (MOH) Stock?
- Molina to End Its Medicare Advantage Drug Plans on December 31. The Decision Was Announced in February. The Letter Telling Members Arrives in October
- Molina Healthcare (MOH) Pulls Back Following Recent Weakness, Is The Stock Cheap?
- Molina Healthcare (MOH) Jumped 70.7% in Q2: Why the Stock Rally Was Enough to Sell
- Health Insurance Providers Stocks Q2 Recap: Benchmarking Molina Healthcare (NYSE:MOH)
- Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
- UNH vs. MOH: Which Managed Care Stock Looks More Attractive?
- 3 Greek Energy Stocks With Pricing Power As Power Bills Rise
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Molina Healthcare Inc.
Full MOH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.